Velaglucerase alfa
Description
Type: biotech
Groups: Array
Indication: Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.
Accession Number: DB06720 ( DB06720)
Description: Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Structure:
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Vpriv | injection, powder, lyophilized, for solution | 2.5 mg/mL | intravenous | 26-02-2010 | US | |
Vpriv | powder for solution | 400 unit | intravenous | 22-11-2010 | Canada |
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
Vpriv | injection, powder, lyophilized, for solution | 2.5 mg/mL | intravenous | 26-02-2010 | US | |
Vpriv | powder for solution | 400 unit | intravenous | 22-11-2010 | Canada |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
Brand Name | Ingredients |
---|---|
Vpriv | Velaglucerase alfa |
Vpriv | Velaglucerase alfa |
Brand Name | Ingredients |
---|---|
Vpriv | Velaglucerase alfa |
Vpriv | Velaglucerase alfa |
Categories
- Enzymes
Pharmacology
Pharmacodynamics: Not Available
Mechanism of action: Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.
Absorption: Not Available
Volume of distribution:
- The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight).
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: 11-12 minutes.
Clearance: Not Available
Toxicity: Not Available
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
- Not Available
Packagers:
- Not Available
Dosage forms
Form | Route | Strength |
---|---|---|
Injection, powder, lyophilized, for solution | intravenous | 2.5 mg/mL |
Powder for solution | intravenous | 400 unit |
Form | Route | Strength |
---|---|---|
Injection, powder, lyophilized, for solution | intravenous | 2.5 mg/mL |
Powder for solution | intravenous | 400 unit |
Prices
Unit description | Cost | Unit |
---|
Unit description | Cost | Unit |
---|
Patents
Country | Patent Number | Approved | Expires (estimated) |
---|---|---|---|
7138262 | United States | 2006-11-21 | 2020-08-18 |
Interactions
Drug | Interaction |
---|
Drug | Interaction |
---|
Food Interactions:
- Not Available
Taxonomy
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Not Available
substituent:
- Not Available
References
General Reference: # Pastores GM: Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs. 2010 Apr;11(4):472-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20336596 # Vairo F, Netto C, Dorneles A, Mittelstadt S, Wilke M, Doneda D, Michelin K, Ribeiro CB, Quevedo A, Vieira T, Nalin T, Lueska S, Schwartz IV: Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD Rep. 2013 Feb 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23430813
External Links:
Resource | Link |
---|---|
RxList | http://www.rxlist.com/vpriv-drug.htm |
PDRhealth | http://www.pdrhealth.com/info/v1us/vpriv |
Drugs.com | http://www.drugs.com/vpriv.html3 |
Resource | Link |
---|---|
RxList | http://www.rxlist.com/vpriv-drug.htm |
PDRhealth | http://www.pdrhealth.com/info/v1us/vpriv |
Drugs.com | http://www.drugs.com/vpriv.html3 |
ATC Codes:
- Array
AHFS Codes:
- Not Available
MSDS: Download